What is Bloom Burton’s Forecast for TSE:MBX FY2025 Earnings?

Microbix Biosystems Inc. (TSE:MBX) – Investment analysts at Bloom Burton decreased their FY2025 earnings per share (EPS) estimates for shares of Microbix Biosystems in a report issued on Thursday, June 5th. Bloom Burton analyst D. Martin now expects that the company will post earnings per share of ($0.01) for the year, down from their previous forecast of $0.01. Bloom Burton has a “Moderate Buy” rating on the stock. The consensus estimate for Microbix Biosystems’ current full-year earnings is $0.02 per share. Bloom Burton also issued estimates for Microbix Biosystems’ FY2026 earnings at ($0.01) EPS and FY2027 earnings at $0.01 EPS.

Microbix Biosystems Price Performance

Shares of TSE MBX opened at C$0.30 on Monday. The company has a debt-to-equity ratio of 22.61, a quick ratio of 5.57 and a current ratio of 7.15. Microbix Biosystems has a 52 week low of C$0.29 and a 52 week high of C$0.55. The stock has a market capitalization of C$39.51 million, a P/E ratio of 11.43 and a beta of 0.34. The stock’s fifty day moving average is C$0.35 and its 200 day moving average is C$0.39.

About Microbix Biosystems

Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.